EUVIMEDEUVIMED entdecken
Crossref

Current Therapy for Basal Cell Carcinoma and the Potential Role for Immunotherapy With Checkpoint Inhibitors

Sarah E. Fenton, Jeffrey A. Sosman, Sunandana Chandra

Clinical Skin Cancer · 2017-12 · 2 (1-2) · 59-65

DOI: 10.1016/j.clsc.2017.11.001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Skin Cancer, 2017-12. Verfasst von Sarah E. Fenton und 2 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 97 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Fenton, S. E., Sosman, J. A., & Chandra, S. (2017). Current Therapy for Basal Cell Carcinoma and the Potential Role for Immunotherapy With Checkpoint Inhibitors. Clinical Skin Cancer, 2(1-2), 59-65. https://doi.org/10.1016/j.clsc.2017.11.001

Vancouver

Fenton SE, Sosman JA, Chandra S. Current Therapy for Basal Cell Carcinoma and the Potential Role for Immunotherapy With Checkpoint Inhibitors. Clinical Skin Cancer. 2017;2(1-2):59-65. doi:10.1016/j.clsc.2017.11.001

BibTeX
@article{Fenton2017,
  author = {Fenton, Sarah E. and Sosman, Jeffrey A. and Chandra, Sunandana},
  title = {Current Therapy for Basal Cell Carcinoma and the Potential Role for Immunotherapy With Checkpoint Inhibitors},
  journal = {Clinical Skin Cancer},
  year = {2017},
  volume = {2},
  number = {1-2},
  pages = {59--65},
  doi = {10.1016/j.clsc.2017.11.001}
}
Kostenlos starten →